Partners for JLABS @ Toronto include Janssen Inc., MaRS Innovation and seven of MI's 15 member institutions
TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto.
This announcement has been covered in the Toronto Star, Metro News Canada, Sing Tao Daily, OurWindsor.ca, FierceBiotech, BioCentury, MedCity News, BioSpace, Biotechnology Focus, Lab Product News, ChinaNews.com, Pan European Networks, Economic ...
Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies
TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer's disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation's president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals:
The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Dr. Raphael Hofstein.
The article explores the role life sciences assets, financing and talented management--the three Ms--must play in revitalizing Canada's biotechnology sector:
At the close of the 20th century, Canada was perceived as a key contributor to the success of the global biotech voyage.
You know what happened next: the mechanisms to fund early ventures collapsed together with the collapse of the ...
In a January 24, 2014 Biotechnology Focus cover article, author Shawn Lawrence discusses MaRS Innovation President and CEO Dr. Raphael (Rafi) Hofstein's recent visit to learn more of the emerging science and technology markets in Singapore and Japan.
The trip allowed Hofstein to discuss current MI projects, specifically start-ups XLV Diagnostics Inc. and DVLR Therapeutics Inc., whose products could benefit from Singapore's proximity to medical technology markets in India and China.
Hofstein joined other delegates from Canada, including Dr. Mark Poznansky, president and CEO of the ...
In a November 25 article in Biotechnology Focus magazine, author Shawn Lawrence highlights Stem Cell Therapeutics and Trillium Therapeutics Inc. coming together in a reverse merger that creates more opportunities to advance early-stage research.
The article profiles Dr. Aaron Schimmer and his discovery that Tigecycline is effective in killing leukemia cells and leukemia stem cells by shutting down their energy supply.
Here's a quote from Lawrence's article:
“Dr. Schimmer’s research is focused on drug repurposing – finding new indications for approved therapeutics. Focusing on established drugs ...
Collaboration will advance early-stage technologies and identify high-potential opportunities related to human health
TORONTO, Nov. 25, 2013 - MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, today announced a new collaboration with Johnson & Johnson Innovation and its affiliate Janssen, Inc., in Canada to advance early-stage technologies related to human health in therapeutics, medical devices, and diagnostics.
This announcement was covered by Biotechnology Focus and the Village Gamer blog.
Through the collaboration, MaRS Innovation and technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will jointly ...
Bedside Clinical Systems to bring paediatric care solution to U.S. hospitals
TORONTO, Canada (October 24, 2013) — Bedside Clinical Systems (BCS)’s flagship solution, Bedside Paediatric Early Warning System (BedsidePEWSTM), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). For the complete BedsidePEWS™ FDA Medical Device listing (K124038), click here.
This story was covered in Biotechnology Focus.
BedsidePEWSTM tracks a patient’s vital signs, such as heart rate and blood pressure, as part of routine clinical assessments and outputs a single score to ...
MaRS Innovation's (MI) projects and partnerships earned three separate article mentions in the December 2012 issue of Biotechnology Focus, including:
MI and UHN's partnership with Stem Cell Therapeutics was covered in the magazine's Dealmakers subsection. Read the write-up on the Biotechnology Focus website.
Cellax, a licensable technology that may produce a nanotechonology-based cancer drug, was highlighted in the magazine's Business Corner section (read the write-up). Cellax is a joint project between MI and the Ontario Institute for Cancer Research.
MaRS Innovation's ...